Pharmaceuticals Search Engine [selected websites]

Monday, June 11, 2012

ReproCELL launches Alzheimer’s disease model based on iPS-derived human neuronal cells

ReproCELL 7th June 2012 - ReproCELL, Inc. (CEO: Chikafumi Yokoyama PhD) announces that the company will start commercializing human iPS-derived neurons in which an Alzheimer’s disease related gene has been incorporated.

ReproCELL’s scientists have successfully incorporated a gene related to Alzheimer’s disease using homologous recombinant genetic engineering technology into undifferentiated human iPS cells and then differentiated them into neurons. In these cells, it has been confirmed that amyloid beta 42 is accumulated at higher levels compared to normal neurons. This phenomena is similar to what is observed in neurons of Alzheimer’s patients. Accordingly, ReproCELL’s scientists believe the newly developed iPS cells can be useful for drug screening to identify new therapeutic molecules to treat Alzheimer’s disease patients.... ReproCELL's Press Release -